caffeine has been researched along with thiotepa in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hansson, K | 1 |
| Mourelatos, DC | 1 |
| Sturelid, S | 1 |
| Kihlman, BA; Sturelid, S | 1 |
| Hartley-Asp, B | 1 |
| Chang, JD; Fingert, HJ; Pardee, AB | 1 |
| Chebotarev, AN; Golovina, ME; Smirnova, TD | 1 |
| Fujii, T; Nakatsuka, T | 1 |
| Hansson, K; Kihlman, BA; Palitti, F; Tanzarella, C | 1 |
| Fingert, HJ; Kindy, RL; Pardee, AB | 1 |
1 review(s) available for caffeine and thiotepa
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for caffeine and thiotepa
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Caffeine enhancement of chromosomal aberrations induced by thiotepa in bone marrow cells of mice.
Topics: Animals; Bone Marrow; Caffeine; Chromosome Aberrations; Chromosomes; Drug Synergism; Male; Mice; Thiotepa | 1978 |
Enhancement by caffeine of sister-chromatid exchange frequency induced by antineoplastic agents in human lymphocytes.
Topics: Caffeine; Chromatids; Crossing Over, Genetic; DNA Repair; Drug Synergism; Humans; Lymphocytes; Thiotepa; Time Factors | 1979 |
Enhancement by caffeine of cell killing and chromosome damage in Chinese hamster cells treated with thiotepa.
Topics: Animals; Caffeine; Cell Line; Cell Survival; Chromosome Aberrations; Chromosomes; Clone Cells; Cricetinae; Drug Synergism; Male; Mitosis; Thiotepa | 1977 |
Enhancement by methylated oxypurines of the frequency of induced chromosomal aberrations.
Topics: Animals; Caffeine; Cell Line; Cells, Cultured; Chromosome Aberrations; Chromosomes; Cricetinae; Drug Synergism; Methylation; Mutation; Plants; Purines; Theobromine; Theophylline; Thiotepa; Uric Acid | 1975 |
Enhancement by methylated oxypurines of the frequency of induced chromosomal aberrations. IV. The dependence of the potentiation on the type of material.
Topics: Caffeine; Cell Line; Chromosome Aberrations; Drug Synergism; Maleic Hydrazide; Mitomycins; Plants; Thiotepa; Time Factors | 1976 |
Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents.
Topics: Alkylating Agents; Caffeine; Cell Cycle; Cell Line; Cell Survival; Chromosome Aberrations; Chromosomes; Drug Synergism; Humans; Interphase; Mechlorethamine; Pentoxifylline; Theobromine; Thiotepa; Urinary Bladder Neoplasms | 1986 |
[Simultaneous estimation of sister chromatid exchange and evaluation of cell cycle delay].
Topics: Animals; Caffeine; Cell Cycle; Cells, Cultured; Cricetinae; Cricetulus; Cytarabine; Hydroxyurea; Mitosis; Sister Chromatid Exchange; Thiotepa | 1988 |
Potentiating effects of caffeine on teratogenicity of alkylating agents in mice.
Topics: Abnormalities, Drug-Induced; Abnormalities, Radiation-Induced; Alkylating Agents; Animals; Antibiotics, Antineoplastic; Caffeine; Chlorambucil; Cyclophosphamide; Drug Synergism; Embryo Implantation; Female; Fetal Resorption; Methylnitronitrosoguanidine; Mice; Mice, Inbred Strains; Mitomycin; Mitomycins; Pregnancy; Teratogens; Thiotepa | 1983 |
Influence of caffeine and 3-aminobenzamide in G2 on the frequency of chromosomal aberrations induced by thiotepa, mitomycin C and N-methyl-N-nitro-N'-nitrosoguanidine in human lymphocytes.
Topics: Benzamides; Caffeine; Cell Cycle; Cells, Cultured; Chromosome Aberrations; DNA Repair; Drug Synergism; Humans; Lymphocytes; Methylnitronitrosoguanidine; Mitomycins; Thiotepa | 1984 |
Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa.
Topics: Antineoplastic Combined Chemotherapy Protocols; Caffeine; Carcinoma, Transitional Cell; Cell Division; Cell Line; Cell Survival; Doxorubicin; Drug Synergism; Humans; Interphase; Theobromine; Thiotepa; Time Factors; Urinary Bladder Neoplasms; Xanthines | 1984 |